Andrea Botti
@ausl.re.it
AUSL IRCCS Reggio Emilia
Scopus Publications
- Real-time detection of extravasation events of diagnostic and therapeutic radiopharmaceuticals in oncology
Noemi Cucurachi, Federica Fioroni, Elisa Grassi, Nicola Panico, Laura Verzellesi, Andrea Botti, Alessandro Fraternali, Massimo Roncali, Rexhep Durmo, Angelina Filice, Mauro Iori
Plos One, 2026
Background Radiopharmaceutical extravasation—when injected activity remains in soft tissue rather than entering the bloodstream—can compromise quantification in positron emission tomography/computed tomography (PET/CT) and, in therapeutic settings, deliver high local radiation doses. These effects may lead to inaccurate Standardized Uptake Value (SUV) measurements, potential misdiagnosis, repeat examinations, and to avoid patient risk. We assessed a simple, real-time approach for detecting extravasation during administration to enable immediate management and quantitative correction. Results Real-time monitoring with portable gamma detectors was applied to 885 diagnostic PET examinations ( 18 F-FDG, 68 Ga-DOTATOC/TATE, 68 Ga-PSMA-11) and 15 administrations of 177 Lu-DOTATATE therapy. In the diagnostic cohort, 53 extravasation events were identified and confirmed on PET images. Analysis of dose-rate–time curves yielded practical thresholds for extravasation detection: Δp in nor = 0.30 and ΔR t = 388 µSv/h. A statistically significant association was observed between SUV correction factors and specific curve parameters, enabling prospective adjustment of SUV before image interpretation. In the therapeutic cohort, one extravasation was observed, with an estimated absorbed self-dose of 11.6 Gy to the affected region. The monitoring enabled timely intervention that limited unnecessary exposure and workflow disruption. Feasibility analyses indicated that, for diagnostic procedures, a single detector can be sufficient for reliable extravasation identification and for deriving SUV correction factors. Conclusions A real-time, detector-based strategy can identify radiopharmaceutical extravasation during injection, support immediate mitigation, and preserve diagnostic accuracy by allowing early SUV correction. In therapeutic applications, it can reduce risk by prompting management of rare but consequential events. The operational simplicity, low cost, and effectiveness demonstrated across both diagnostic and therapeutic scenarios support integration of this approach into routine clinical practice, with the added practicality that a single detector appears adequate for diagnostic workflows. - A Pipeline for MRI-Guided dose painting by number radiation Therapy: GLIORAD − a phase I-II clinical trial in recurrent glioblastoma
Andrea Botti, Roberto Sghedoni, Matteo Orlandi, Giulia Paolani, Patrizia Ciammella, Lucia Giaccherini, Cinzia Iotti, Mauro Iori
Physica Medica, 2026 - Low-Dose Radiotherapy for Primary Cutaneous Indolent B-Cell Lymphomas: a Multicenter Retrospective Study
E Alì, G Simontacchi, M Levis, F Iori, S Gambara, EM Cuffini, N Pimpinelli, V Grandi, A Botti, G Paolani, C Iotti, U Ricardi, P Ciammella
Radiotherapy and Oncology, 2026 - Using HistoQC to predict disagreement on human epidermal growth factor receptor 2 (HER2) assessment
Laura Verzellesi, Moira Ragazzi, Andrea Botti, Giacomo Santandrea, Andrew Janowczyk, Luca Bottazzi, Alessandra Bisagni, Ione Tamagnini, Giorgio Gardini, Saverio Coiro, Elisa Gasparini, Mauro Iori
Physica Medica, 2025 - Locally advanced NSCLC: overview of real-world pattern of recurrence in durvalumab era (LEOPARD trial)
P. Ciammella, F. Iori, P. Borghetti, M. Galaverni, E. Alì, M. Tiseo, M. Pagano, M. Sepulcri, V. Scotti, N. GiajLevra, M. Marcenaro, N. Simoni, V. Nardone, A. Botti, S. Cozzi, A. Bruni
Lung Cancer, 2025 - Spatially Fractionated Radiation Therapy for Palliation in Patients With Large Cancers: A Retrospective Study
Federico Iori, Valeria Trojani, Alice Zamagni, Patrizia Ciammella, Mauro Iori, Andrea Botti, Cinzia Iotti
Advances in Radiation Oncology, 2025
Purpose: Spatially fractionated radiation therapy (SFRT) is an irradiation technique developed to improve large cancer response. Although preliminary studies report highly positive results, data are still limited. The aim of this retrospective monocentric study was to investigate SFRT safety and activity. Methods and Materials: We analyzed all patients who underwent SFRT as a palliative treatment for large solid extracranial cancer (>4.5 cm) at our institution. The primary endpoint was objective response rate assessment at 3 months. Additionally, patients' antalgic response, target volume reduction, and performance status modification were measured. Toxicity data were recorded. Results: , 32%-69%; range, 6%-80%). At 6 months, all patients were free from local disease progression. All patients reported an antalgic response with a rapid onset. All treatment-related toxicities occurred within 1 month after SFRT and quickly recovered. No acute toxicity ≥ grade 3 and late toxicity was reported. No patient experienced a worsening in performance status. Conclusions: Our results provide further evidence supporting SFRT as a safe and promising option for palliative patients affected by large neoplastic lesions. - Refining Treatment Planning in STereotactic Arrhythmia Radioablation: Benchmark Results and Consensus Statement From the STOPSTORM.eu Consortium
Valeria Trojani, Melanie Grehn, Andrea Botti, Brian Balgobind, Alessandro Savini, Judit Boda-Heggemann, Marcin Miszczyk, Olgun Elicin, David Krug, Nicolaus Andratschke, Daniel Schmidhalter, Wouter van Elmpt, Marta Bogowicz, Javier de Areba Iglesias, Lukasz Dolla, Stefanie Ehrbar, Enric Fernandez-Velilla, Jens Fleckenstein, Domingo Granero, Dominik Henzen, Coen Hurkmans, Anne Kluge, Lukas Knybel, Sandy Loopeker, Alfredo Mirandola, Veronica Richetto, Gianluisa Sicignano, Veronique Vallet, Bram van Asselen, Esben Worm, Etienne Pruvot, Joost Verhoeff, Martin Fast, Mauro Iori, Oliver Blanck
International Journal of Radiation Oncology Biology Physics, 2025
PURPOSE: STereotactic Arrhythmia Radioablation (STAR) showed promising results in patients with refractory ventricular tachycardia. However, clinical data are scarce and heterogeneous. The STOPSTORM.eu consortium was established to investigate and harmonize STAR in Europe. The primary goal of this benchmark study was to investigate current treatment planning practice within the STOPSTORM project as a baseline for future harmonization. METHODS AND MATERIALS: Planning target volumes (PTVs) overlapping extracardiac organs-at-risk and/or cardiac substructures were generated for 3 STAR cases. Participating centers were asked to create single-fraction treatment plans with 25 Gy dose prescriptions based on in-house clinical practice. All treatment plans were reviewed by an expert panel and quantitative crowd knowledge-based analysis was performed with independent software using descriptive statistics for International Commission on Radiation Units and Measurements report 91 relevant parameters and crowd dose-volume histograms. Thereafter, treatment planning consensus statements were established using a dual-stage voting process. RESULTS: ranged from 25.5 to 34.6 Gy, demonstrating a large variety of dose inhomogeneity. Estimated treatment times without motion compensation or setup ranged from 2 to 80 minutes. For the consensus statements, a strong agreement was reached for beam technique planning, dose calculation, prescription methods, and trade-offs between target and extracardiac critical structures. No agreement was reached on cardiac substructure dose limitations and on desired dose inhomogeneity in the target. CONCLUSIONS: This STOPSTORM multicenter treatment planning benchmark study not only showed strong agreement on several aspects of STAR treatment planning, but also revealed disagreement on others. To standardize and harmonize STAR in the future, consensus statements were established; however, clinical data are urgently needed for actionable guidelines for treatment planning. - LatticeOpt: An automatic tool for planning optimisation of spatially fractionated stereotactic body radiotherapy
Andrea Botti, Domenico Finocchiaro, Nicola Panico, Valeria Trojani, Giulia Paolani, Federico Iori, Roberto Sghedoni, Elisabetta Cagni, Daniele Lambertini, Patrizia Ciammella, Cinzia Iotti, Mauro Iori
Physica Medica, 2024 - CCL18, CHI3L1, ANG2, IL-6 systemic levels are associated with the extent of lung damage and radiomic features in SARS-CoV-2 infection
Ilaria Ferrigno, Laura Verzellesi, Marta Ottone, Martina Bonacini, Alessandro Rossi, Giulia Besutti, Efrem Bonelli, Rossana Colla, Nicola Facciolongo, Elisabetta Teopompi, Marco Massari, Pamela Mancuso, Anna Maria Ferrari, Pierpaolo Pattacini, Valeria Trojani, Marco Bertolini, Andrea Botti, Alessandro Zerbini, Paolo Giorgi Rossi, Mauro Iori, Carlo Salvarani, Stefania Croci
Inflammation Research, 2024 - Redetermination of PD-L1 expression after chemio-radiation in locally advanced PDL1 negative NSCLC patients: retrospective multicentric analysis
Patrizia Ciammella, Salvatore Cozzi, Paolo Borghetti, Marco Galaverni, Valerio Nardone, Maria Paola Ruggieri, Matteo Sepulcri, Vieri Scotti, Alessio Bruni, Francesca Zanelli, Roberto Piro, Elena Tagliavini, Andrea Botti, Federico Iori, Emanuele Alì, Chiara Bennati, Marcello Tiseo
Frontiers in Oncology, 2024
BackgroundChemoradiation therapy (CRT) is the treatment of choice for locally advanced non-small cell lung cancer (LA-NSCLC). Several clinical trials that combine programmed cell death 1 (PD1) axis inhibitors with radiotherapy are in development for patients with LA-NSCLC. However, the effect of CRT on tumor cells programmed cell death ligand-1 (PD-L1) expression is unknown.MethodsIn this multicentric retrospective study, we analyzed paired NSCLC specimens that had been obtained pre- and post-CRT. PD-L1 expression on tumor cells was studied by immunohistochemistry. The purpose of this study was to evaluate the feasibility, risk of complications, and clinical relevance of performing re-biopsy after CRT in patients with PD-L1 negative LA-NSCLC.ResultsOverall, 31 patients from 6 centers with PD-L1 negative LA-NSCLC were analyzed. The percentage of tumor cells with PD-L1 expression significantly increased between pre- and post-CRT specimens in 14 patients (45%). Nine patients had unchanged PD-L1 expression after CRT, in five patients the rebiopsy material was insufficient for PD-L1 analysis and in two patients no tumor cells at rebiopsy were found. The post-rebiopsy complication rate was very low (6%). All patients with positive PD-L1 re-biopsy received Durvalumab maintenance after CRT, except one patient who had a long hospitalization for tuberculosis reactivation. Median PFS of patients with unchanged or increased PD-L1 expression was 10 and 16.9 months, respectively.ConclusionCRT administration can induce PD-L1 expression in a considerable fraction of PD-L1 negative patients at baseline, allowing them receiving the maintenance Durvalumab in Europe. Hence, after a definitive CRT, PD-L1 redetermination should be considered in patients with LA-NSCLC PD-L1 negative, to have a better selection of maintenance Durvalumab candidates. - Safety injections of nuclear medicine radiotracers: towards a new modality for a real-time detection of extravasation events and 18F-FDG SUV data correction
Mauro Iori, Elisa Grassi, Lorenzo Piergallini, Greta Meglioli, Andrea Botti, Giada Sceni, Noemi Cucurachi, Laura Verzellesi, Domenico Finocchiaro, Annibale Versari, Beatrice Fraboni, Federica Fioroni
Ejnmmi Physics, 2023 - Machine and Deep Learning Algorithms for COVID-19 Mortality Prediction Using Clinical and Radiomic Features
Laura Verzellesi, Andrea Botti, Marco Bertolini, Valeria Trojani, Gianluca Carlini, Andrea Nitrosi, Filippo Monelli, Giulia Besutti, Gastone Castellani, Daniel Remondini, Gianluca Milanese, Stefania Croci, Nicola Sverzellati, Carlo Salvarani, Mauro Iori
Electronics Switzerland, 2023 - A Monte Carlo Calibration Approach For A Dual-Energy CT System
LORENZO ISOLAN, ANDREA FORMOSI, FRANCESCO TEODORI, ANDREA BOTTI, MARCO BERTOLINI, DOMENICO FINOCCHIARO, MAURO IORI, MARCO SUMINI
Journal of Mechanics in Medicine and Biology, 2023 - Good clinical practice and the use of hypofractionation radiation schedules as weapons to reduce the risk of COVID-19 infections in radiation oncology unit: A mono-institutional experience
Salvatore Cozzi, MariaPaola Ruggieri, Lilia Bardoscia, Masoumeh Najafi, Gladys Blandino, Lucia Giaccherini, Moana Manicone, Dafne Ramundo, Ala Rosca, DarioSalvatore Solla, Andrea Botti, Daniele Lambertini, Patrizia Ciammella, Cinzia Iotti
Journal of Cancer Research and Therapeutics, 2023 - Linac-based stereotactic salvage reirradiation for intraprostatic prostate cancer recurrence: toxicity and outcomes
Salvatore Cozzi, Sebastiano Finocchi Ghersi, Lilia Bardoscia, Masoumeh Najafi, Gladys Blandino, Emanuele Alì, Matteo Augugliaro, Federica Vigo, Maria Paola Ruggieri, Raffaele Cardano, Lucia Giaccherini, Federico Iori, Andrea Botti, Valeria Trojani, Patrizia Ciammella, Cinzia Iotti
Strahlentherapie Und Onkologie, 2023 - Moderately Hypofractionated Helical Tomotherapy for Prostate Cancer: Ten-year Experience of a Mono-institutional Series of 415 Patients
SALVATORE COZZI, MARIA PAOLA RUGGIERI, EMANUELE ALÌ, SEBASTIANO FINOCCHI GHERSI, FEDERICA VIGO, MATTEO AUGUGLIARO, LUCIA GIACCHERINI, FEDERICO IORI, MASOUMEH NAJAFI, LILIA BARDOSCIA, ANDREA BOTTI, VALERIA TROJANI, PATRIZIA CIAMMELLA, CINZIA IOTTI
In Vivo, 2023 - Clinical Effects of Immuno-Oncology Therapy on Glioblastoma Patients: A Systematic Review
Masoumeh Najafi, Amin Jahanbakhshi, Sebastiano Finocchi Ghersi, Lucia Giaccherini, Andrea Botti, Francesco Cavallieri, Jessica Rossi, Federico Iori, Cinzia Iotti, Patrizia Ciammella, Mohsen Nabiuni, Marzieh Gomar, Omid Rezaie, Salvatore Cozzi
Brain Sciences, 2023 - Thoracic Radiotherapy in Extensive Disease Small Cell Lung Cancer: Multicenter Prospective Observational TRENDS Study
Salvatore Cozzi, Alessio Bruni, Maria Paola Ruggieri, Paolo Borghetti, Vieri Scotti, Davide Franceschini, Michele Fiore, Maria Taraborrelli, Fabrizio Salvi, Marco Galaverni, Luisa Savoldi, Luca Braglia, Andrea Botti, Sebastiano Finocchi Ghersi, Giaj-Levra Niccolò, Frank Lohr, Cinzia Iotti, Patrizia Ciammella
Cancers, 2023 - Ductal prostate cancer: Clinical features and outcomes from a multicenter retrospective analysis and overview of the current literature
Salvatore Cozzi, Lilia Bardoscia, Masoumeh Najafi, Sefik Igdem, Luca Triggiani, Stefano Maria Magrini, Andrea Botti, Ferran Guedea, Laura Melocchi, Patrizia Ciammella, Cinzia Iotti, Cristina Gutierrez
Current Urology, 2022 - How a very large sarcomatoid lung cancer was efficiently managed with lattice radiation therapy: a case report
Federico Iori, Andrea Botti, Patrizia Ciammella, Salvatore Cozzi, Matteo Orlandi, Mauro Iori, Cinzia Iotti
Annals of Palliative Medicine, 2022 - The Use of Cardiac Stereotactic Radiation Therapy (SBRT) to Manage Ventricular Tachycardia: A Case Report, Review of the Literature and Technical Notes
Salvatore Cozzi, Nicola Bottoni, Andrea Botti, Valeria Trojani, Emanuele Alì, Sebastiano Finocchi Ghersi, Federica Cremaschi, Federico Iori, Patrizia Ciammella, Mauro Iori, Cinzia Iotti
Journal of Personalized Medicine, 2022 - Evaluating the Quality of Patient-Specific Deformable Image Registration in Adaptive Radiotherapy Using a Digitally Enhanced Head and Neck Phantom
Elisabetta Cagni, Andrea Botti, Matteo Orlandi, Marco Galaverni, Cinzia Iotti, Mauro Iori, Geraint Lewis, Emiliano Spezi
Applied Sciences Switzerland, 2022 - Safety of Inhomogeneous Dose Distribution IMRT for High-Grade Glioma Reirradiation: A Prospective Phase I/II Trial (GLIORAD TRIAL)
Patrizia Ciammella, Salvatore Cozzi, Andrea Botti, Lucia Giaccherini, Roberto Sghedoni, Matteo Orlandi, Manuela Napoli, Rosario Pascarella, Anna Pisanello, Marco Russo, Francesco Cavallieri, Maria Paola Ruggieri, Silvio Cavuto, Luisa Savoldi, Cinzia Iotti, Mauro Iori
Cancers, 2022 - Prognostic factors, efficacy, and toxicity of involved-node stereotactic body radiation therapy for lymph node oligorecurrent prostate cancer: An investigation of 117 pelvic lymph nodes
Salvatore Cozzi, Andrea Botti, Giorgia Timon, Gladys Blandino, Masoumeh Najafi, Moana Manicone, Lilia Bardoscia, Maria Paola Ruggieri, Patrizia Ciammella, Cinzia Iotti
Strahlentherapie Und Onkologie, 2022 - Novel Harmonization Method for Multi-Centric Radiomic Studies in Non-Small Cell Lung Cancer
Marco Bertolini, Valeria Trojani, Andrea Botti, Noemi Cucurachi, Marco Galaverni, Salvatore Cozzi, Paolo Borghetti, Salvatore La Mattina, Edoardo Pastorello, Michele Avanzo, Alberto Revelant, Matteo Sepulcri, Chiara Paronetto, Stefano Ursino, Giulia Malfatti, Niccolò Giaj-Levra, Lorenzo Falcinelli, Cinzia Iotti, Mauro Iori, Patrizia Ciammella
Current Oncology, 2022 - Stereotactic Body Radiation Therapy (SBRT) for Oligorecurrent/Oligoprogressive Mediastinal and Hilar Lymph Node Metastasis: A Systematic Review
Salvatore Cozzi, Emanuele Alì, Lilia Bardoscia, Masoumeh Najafi, Andrea Botti, Gladys Blandino, Lucia Giaccherini, Maria Paola Ruggieri, Matteo Augugliaro, Federico Iori, Angela Sardaro, Cinzia Iotti, Patrizia Ciammella
Cancers, 2022 - State of the Art in Combination Immuno/Radiotherapy for Brain Metastases: Systematic Review and Meta-Analysis
Masoumeh Najafi, Amin Jahanbakhshi, Marzieh Gomar, Cinzia Iotti, Lucia Giaccherini, Omid Rezaie, Francesco Cavallieri, Letizia Deantonio, Lilia Bardoscia, Andrea Botti, Angela Sardaro, Salvatore Cozzi, Patrizia Ciammella
Current Oncology, 2022 - The Role of Interstitial Brachytherapy for Breast Cancer Treatment: An Overview of Indications, Applications, and Technical Notes
Salvatore Cozzi, Matteo Augugliaro, Patrizia Ciammella, Andrea Botti, Valeria Trojani, Masoumeh Najafi, Gladys Blandino, Maria Paola Ruggieri, Lucia Giaccherini, Emanuele Alì, Federico Iori, Angela Sardaro, Sebastiano Finocchi Ghersi, Letizia Deantonio, Cristina Gutierrez Miguelez, Cinzia Iotti, Lilia Bardoscia
Cancers, 2022 - Mortality Prediction of COVID-19 Patients Using Radiomic and Neural Network Features Extracted from a Wide Chest X-ray Sample Size: A Robust Approach for Different Medical Imbalanced Scenarios
Mauro Iori, Carlo Di Castelnuovo, Laura Verzellesi, Greta Meglioli, Davide Giosuè Lippolis, Andrea Nitrosi, Filippo Monelli, Giulia Besutti, Valeria Trojani, Marco Bertolini, Andrea Botti, Gastone Castellani, Daniel Remondini, Roberto Sghedoni, Stefania Croci, Carlo Salvarani
Applied Sciences Switzerland, 2022 - Adenoid Cystic Carcinoma/Basal Cell Carcinoma of the Prostate: Overview and Update on Rare Prostate Cancer Subtypes
Salvatore Cozzi, Lilia Bardoscia, Masoumeh Najafi, Andrea Botti, Gladys Blandino, Matteo Augugliaro, Moana Manicone, Federico Iori, Lucia Giaccherini, Angela Sardaro, Cinzia Iotti, Patrizia Ciammella
Current Oncology, 2022 - Variations in Head and Neck Treatment Plan Quality Assessment Among Radiation Oncologists and Medical Physicists in a Single Radiotherapy Department
Elisabetta Cagni, Andrea Botti, Linda Rossi, Cinzia Iotti, Mauro Iori, Salvatore Cozzi, Marco Galaverni, Ala Rosca, Roberto Sghedoni, Giorgia Timon, Emiliano Spezi, Ben Heijmen
Frontiers in Oncology, 2021 - Use of knowledge based DVH predictions to enhance automated re-planning strategies in head and neck adaptive radiotherapy
Elisabetta Cagni, Andrea Botti, Agnese Chendi, Mauro Iori, Emiliano Spezi
Physics in Medicine and Biology, 2021 - EPID-based 3D dosimetry for pre-treatment FFF VMAT stereotactic body radiotherapy plan verification using dosimetry CheckTM
Agnese Chendi, Andrea Botti, Matteo Orlandi, Roberto Sghedoni, Mauro Iori, Elisabetta Cagni
Physica Medica, 2021 - Radiation-induced breast angiosarcoma: report of two patients after accelerated partial breast irradiation (APBI) and review of the literature
Salvatore Cozzi, Masoumeh Najafi, Lilia Bardoscia, Maria Paola Ruggieri, Lucia Giaccherini, Gladys Blandino, Andrea Botti, Patrizia Ciammella, Cinzia Iotti
Reports of Practical Oncology and Radiotherapy, 2021 - Management of locally advanced non-small cell lung cancer in the modern era: A national Italian survey on diagnosis, treatment and multidisciplinary approach
Alessio Bruni, Niccolò Giaj-Levra, Patrizia Ciammella, Virginia Maragna, Katia Ferrari, Viola Bonti, Francesco Grossi, Stefania Greco, Carlo Greco, Paolo Borghetti, Davide Franceschini, Enrica Capelletto, Marco Perna, Giuseppe Banna, Stefano Vagge, Editta Baldini, Emilio Bria, Andrea Botti, Marcello Tiseo, Massimiliano Paci, Maria Taraborrelli, Venerino Poletti, Pierluigi Granone, Umberto Ricardi, Silvia Novello, Vieri Scotti
Plos One, 2019 - Role of multidimensional assessment of frailty in predicting outcomes in older patients with glioblastoma treated with adjuvant concurrent chemo-radiation
Lucia Giaccherini, Marco Galaverni, Ilaria Renna, Giorgia Timon, Maria Galeandro, Anna Pisanello, Marco Russo, Andrea Botti, Cinzia Iotti, Patrizia Ciammella
Journal of Geriatric Oncology, 2019 - Analysis of the bias induced by voxel and unstructured mesh Monte Carlo models for the MCNP6 code in orthovoltage applications
Lorenzo Isolan, Marco De Pietri, Mauro Iori, Andrea Botti, Elisabetta Cagni, Marco Sumini
Radiation Effects and Defects in Solids, 2019 - Pareto-optimal plans as ground truth for validation of a commercial system for knowledge-based DVH-prediction
Elisabetta Cagni, Andrea Botti, Yibing Wang, Mauro Iori, Steven F. Petit, Ben J.M. Heijmen
Physica Medica, 2018 - Setup errors in patients with head-neck cancer (HNC), treated using the Intensity Modulated Radiation Therapy (IMRT) technique: How it influences the customised immobilisation systems, patient's pain and anxiety
Massimiliano Contesini, Monica Guberti, Roberta Saccani, Luca Braglia, Cinzia Iotti, Andrea Botti, Emilio Abbati, Marina Iemmi
Radiation Oncology, 2017 - Knowledge-based treatment planning: An inter-technique and inter-system feasibility study for prostate cancer
Elisabetta Cagni, Andrea Botti, Renato Micera, Maria Galeandro, Roberto Sghedoni, Matteo Orlandi, Cinzia Iotti, Luca Cozzi, Mauro Iori
Physica Medica, 2017 - CT-guided biopsy of pulmonary nodules; predictive factors for diagnosis: Is there room for more prognostic factors?
Gabriele Levrini, Antonia Magnani, Roberto Sghedoni, Pierpaolo Pattacini, Marco Bertolini, Andrea Botti, Valentina Iotti
Radiologia Medica, 2017 - Feasibility of voxel-based Dose Painting for recurrent Glioblastoma guided by ADC values of Diffusion-Weighted MR imaging
M. Orlandi, A. Botti, R. Sghedoni, E. Cagni, P. Ciammella, C. Iotti, M. Iori
Physica Medica, 2016 - First application of a pixel-wise analysis on bladder dose-surface maps in prostate cancer radiotherapy
Federica Palorini, Cesare Cozzarini, Stefano Gianolini, Andrea Botti, Viviana Carillo, Cinzia Iotti, Tiziana Rancati, Riccardo Valdagni, Claudio Fiorino
Radiotherapy and Oncology, 2016 - Bladder dose-surface maps and urinary toxicity: Robustness with respect to motion in assessing local dose effects
F. Palorini, A. Botti, V. Carillo, S. Gianolini, I. Improta, C. Iotti, T. Rancati, C. Cozzarini, C. Fiorino
Physica Medica, 2016 - Multi-variable models of large International Prostate Symptom Score worsening at the end of therapy in prostate cancer radiotherapy
Federica Palorini, Tiziana Rancati, Cesare Cozzarini, Ilaria Improta, Viviana Carillo, Barbara Avuzzi, Valeria Casanova Borca, Andrea Botti, Claudio Degli Esposti, Pierfrancesco Franco, Elisabetta Garibaldi, Giuseppe Girelli, Cinzia Iotti, Angelo Maggio, Marcella Palombarini, Alessio Pierelli, Emanuele Pignoli, Vittorio Vavassori, Riccardo Valdagni, Claudio Fiorino
Radiotherapy and Oncology, 2016 - Second tumor induction risk in IMRT for prostate cancer: An unbalanced comparison between surgeryand radiotherapy?
Riccardo Calandrino, Lucia Perna, Maria Luisa Belli, Andrea Botti, Mauro Cattaneo, Claudio Fiorino, Cesare Cozzarini, Mauro Iori
Health Physics, 2015 - Pre-treatment and in-vivo dosimetry of Helical Tomotherapy treatment plans using the dosimetry Check system
E Mezzenga, E Cagni, A Botti, M Orlandi, M Iori
Journal of Instrumentation, 2014 - Relationships between bladder dose-volume/surface histograms and acute urinary toxicity after radiotherapy for prostate cancer
Viviana Carillo, Cesare Cozzarini, Tiziana Rancati, Barbara Avuzzi, Andrea Botti, Valeria Casanova Borca, Gabriella Cattari, Francesco Civardi, Claudio Degli Esposti, Pierfrancesco Franco, Giuseppe Girelli, Angelo Maggio, Alessandro Muraglia, Marcella Palombarini, Alessio Pierelli, Emanuele Pignoli, Vittorio Vavassori, Michele Zeverino, Riccardo Valdagni, Claudio Fiorino
Radiotherapy and Oncology, 2014 - Hypofractionated stereotactic radiation therapy for recurrent glioblastoma: Single institutional experience
Patrizia Ciammella, Ala Podgornii, Maria Galeandro, Nunziata D’Abbiero, Anna Pisanello, Andrea Botti, Elisabetta Cagni, Mauro Iori, Cinzia Iotti
Radiation Oncology, 2013 - Hypo-fractionated IMRT for patients with newly diagnosed glioblastoma multiforme: A 6 year single institutional experience
Patrizia Ciammella, Maria Galeandro, Nunziata D’Abbiero, Ala Podgornii, Anna Pisanello, Andrea Botti, Elisabetta Cagni, Mauro Iori, Cinzia Iotti
Clinical Neurology and Neurosurgery, 2013 - Efficiency and effectiveness of an innovative RIS function for patient information reconciliation directly integrated with PACS
Andrea Nitrosi, Marco Bertolini, Pietro Notari, Andrea Botti, Vladimiro Ginocchi, Giulio Tondelli, Mauro Iori, Pierpaolo Pattacini
Journal of Digital Imaging, 2013 - Correlation between surrogates of bladder dosimetry and dose-volume histograms of the bladder wall defined on MRI in prostate cancer radiotherapy
Viviana Carillo, Cesare Cozzarini, Andreina Chietera, Lucia Perna, Stefano Gianolini, Angelo Maggio, Andrea Botti, Tiziana Rancati, Riccardo Valdagni, Claudio Fiorino
Radiotherapy and Oncology, 2012 - Size assessment of breast lesions by means of a computer-aided detection (CAD) system for magnetic resonance mammography
G. Levrini, R. Sghedoni, C. Mori, A. Botti, R. Vacondio, A. Nitrosi, M. Iori, F. Nicoli
Radiologia Medica, 2011 - Contrast detail phantom comparison on a commercially available unit. Digital breast tomosynthesis (DBT) versus full-field digital mammography (FFDM)
Marco Bertolini, Andrea Nitrosi, Giovanni Borasi, Andrea Botti, Davide Tassoni, Roberto Sghedoni, Giulio Zuccoli
Journal of Digital Imaging, 2011 - Application of QC-DR software for acceptance testing and routine quality control of direct digital radiography systems: Initial experiences using the Italian association of physicist in medicine quality control protocol
Andrea Nitrosi, Marco Bertolini, Giovanni Borasi, Andrea Botti, Adriana Barani, Stefano Rivetti, Luisa Pierotti
Journal of Digital Imaging, 2009 - Digital breast tomosynthesis (DBT) versus full field digital mammography (FFDM): Comparison of a system performance using a contrast detail phantom
A. Nitrosi, G. Borasi, M. Bertolini, A. Botti, D. Tassoni, S. Strocchi
Progress in Biomedical Optics and Imaging Proceedings of SPIE, 2009 - SU‐GG‐I‐71: Acceptance and Routine Quality Control in Direct Radiography Systems: Initial Experiences with the Italian Association of Physicist in Medicine Protocol
A Nitrosi, M Bertolini, G Borasi, A Botti, S Rivetti
Medical Physics, 2008 - A filmless radiology department in a full digital regional hospital: Quantitative evaluation of the increased quality and efficiency
Andrea Nitrosi, Giovanni Borasi, Franco Nicoli, Gino Modigliani, Andrea Botti, Marco Bertolini, Pietro Notari
Journal of Digital Imaging, 2007
